跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD19/CD22-CAR T cell
首页
药物
CD19/CD22-CAR T cell
CD19/CD22-CAR T cell
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) - EXPRESSING CELL
EP 3280729 B1
申请人: NOVARTIS AG
优先权: 2015
CN
EP
US
WO
14 件公开
CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
EP 4065157 A1
申请人: NOVARTIS AG
优先权: 2019
CN
EP
US
7 件公开
FULLY HUMANIZED BISPECIFIC CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD22 AND USE THEREOF
EP 4174093 A4
申请人: NANJING IASO BIOTECHNOLOGY CO LTD
优先权: 2020
CN
EP
US
WO
5 件公开
CAR T CELLS FOR TREATING CD19+, CD20+ OR CD22+ TUMORS OR B-CELL DERIVED AUTO-IMMUNE DISEASES
EP 4259650 A1
申请人: OSPEDALE PEDIATRICO BAMBINO GESÙ
优先权: 2020
CN
EP
US
WO
5 件公开
CAR MOLECULE, CELL OR EXOSOME CONTAINING SAME, AND USE THEREOF
EP 4653467 A1
申请人: WUHAN ZHAOZHI BIOTECHNOLOGY CO LTD
优先权: 2023
CN
EP
US
WO
4 件公开
HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME
EP 4252854 A3
申请人: INNOBATION BIO CO LTD
优先权: 2020
CN
EP
US
3 件公开
CD19/22 CAR T-CELL TREATMENT OF HIGH RISK OR RELAPSED PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
EP 4522204 A1
申请人: AUTOLUS LTD
优先权: 2022
EP
US
WO
3 件公开
CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD22, AND CAR-T CELL AND USE THEREOF
WO 2025237062 A1
申请人: SHENZHEN PREGENE BIOPHARMA CO LTD
优先权: 2024
CN
WO
2 件公开
Chimeric antigen receptor targeting CD19 and CD22 and application thereof
CN 117089561 A
申请人: SHANGHAI HRAIN BIOTECHNOLOGY CO LTD
优先权: 2018
CN
Bispecific CAR structure targeting CD19 and CD22 and application of bispecific CAR structure
CN 113493523 A
申请人: CHONGQING PREC BIOTECH CO LTD
优先权: 2020
CN
第 1 / 3 页
上一页
下一页
药物
反馈